慢性NK-LGL白血病中频发TET2体细胞突变且伴独特血细胞减少模式
该研究对慢性NK-LGL白血病进行全基因组测序并建立重测序面板,在58例患者中检测突变。发现TET2突变占28%,STAT3突变占33%,单纯TET2突变者独特地出现血小板减少和免疫抑制治疗耐药。
要点
- TET2突变见于28%(16/58)慢性NK-LGL白血病患者,可为主导性且局限于NK细胞。
- STAT3突变见于33%(19/58)患者,其中7例同时存在TET2突变。
- 单纯TET2突变与血小板减少及免疫抑制剂耐药相关(P=.0074;P=.00466)。
核心结论
- 在慢性NK-LGL白血病中发现TET2突变,并证明其标识一个独特的分子亚型。
研究设计与样本
- 对慢性NK-LGL白血病进行全基因组测序以识别独特突变,开发重测序面板并应用于58例患者。
主要发现
- PIK3CD/PIK3AP1突变见于5%患者,TNFAIP3突变见于10%患者。
- TET2突变见于16/58(28%)患者样本,有证据表明TET2突变可为主导性且 exclusive 于NK组分。
- 减少代表性亚硫酸氢盐测序显示TET2突变样本甲基化模式显著改变。
- TET2和PTPRD(STAT3负调控因子)启动子在额外队列样本中发现甲基化,主要局限于TET2突变组。
- STAT3突变见于19/58(33%)患者样本,其中7例同时有TET2突变。
关键数值与推荐
- 血小板减少和免疫抑制剂耐药仅见于单纯TET2突变患者(Games-Howell事后检验P=.0074;Fisher精确检验P=.00466)。
- STAT3突变患者(包括TET2共突变者)相比STAT3野生型患者有更低的血细胞比容、血红蛋白和中性粒细胞绝对计数(Welch t检验P≤.015)。
临床怎么用
- 对慢性NK-LGL白血病患者进行TET2和STAT3突变检测可能有助于识别分子亚型。
- 单纯TET2突变患者可能预示血小板减少及对免疫抑制治疗耐药,需考虑替代治疗策略。
局限性
- 样本量58例,属于罕见病研究,结果需更大队列验证。
- 研究为探索性,TET2突变的功能机制及临床干预价值尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic natural killer large granular lymphocyte (NK-LGL) leukemia, also referred to as chronic lymphoproliferative disorder of NK cells, is a rare disorder defined by prolonged expansion of clonal NK cells. Similar prevalence of STAT3 mutations in chronic T-LGL and NK-LGL leukemia is suggestive of common pathogenesis. We undertook whole-genome sequencing to identify mutations unique to NK-LGL leukemia. The results were analyzed to develop a resequencing panel that was applied to 58 patients. Phosphatidylinositol 3-kinase pathway gene mutations (PIK3CD/PIK3AP1) and TNFAIP3 mutations were seen in 5% and 10% of patients, respectively. TET2 was exceptional in that mutations were present in 16 (28%) of 58 patient samples, with evidence that TET2 mutations can be dominant and exclusive to the NK compartment. Reduced-representation bisulfite sequencing revealed that methylation patterns were significantly altered in TET2 mutant samples. The promoter of TET2 and that of PTPRD, a negative regulator of STAT3, were found to be methylated in additional cohort samples, largely confined to the TET2 mutant group. Mutations in STAT3 were observed in 19 (33%) of 58 patient samples, 7 of which had concurrent TET2 mutations. Thrombocytopenia and resistance to immunosuppressive agents were uniquely observed in those patients with only TET2 mutation (Games-Howell post hoc test, P = .0074; Fisher's exact test, P = .00466). Patients with STAT3 mutation, inclusive of those with TET2 comutation, had lower hematocrit, hemoglobin, and absolute neutrophil count compared with STAT3 wild-type patients (Welch's t test, P ≤ .015). We present the discovery of TET2 mutations in chronic NK-LGL leukemia and evidence that it identifies a unique molecular subtype.
引用
- Olson TL, Cheon H, Xing JC, et al. Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood. 2021. PMID: 33786584. doi:10.1182/blood.2020005831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。